

Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting
November 21, 2024
Errata – FDA Briefing Document

1. Page 24, Section 3.5.2: “Of the 35 andexanet-treated patients who experienced a thrombotic event, 18 (53%) had the TE during the first 3 days, compared with 1 of 16 patients (6.3%) in the UC group.”

Revised to read: “Of the 35 andexanet-treated patients who experienced a thrombotic event, **17 (49%)** had the TE during the first 3 days, compared with 1 of 16 patients (6.3%) in the UC group.”